ABBV logo AbbVie +
AbbVie
+

AbbVie (ABBV) Business News

Track AbbVie in real time with a live news feed covering AbbVie stock news, official press releases, company announcements, and an archive of historical AbbVie news. ...more

  • Calendar
    Years
    Get instant access
    Sign up for free
    Get instant access
    Sign up for free
    Month
    Jan
    Feb
    Mar
    Apr
    May
    Jun
    Jul
    Aug
    Sep
    Oct
    Nov
    Dec
    Date
    Su
    Mo
    Tu
    We
    Th
    Fr
    Sa
    Selected Filter
    No selection
9:00 AM | Tuesday | Sep 29, 2026 PRNewsWire

AbbVie Partners with Valkai to Apply Advanced AI Across Targeted Areas of Clinical Development

News Thumbnail
8:00 AM | Tuesday | Sep 29, 2026 Business Wire

Ginkgo Datapoints and Apheris Welcome AbbVie, argenx, Lundbeck, and Takeda as Founding Members of the Antibody Developability Consortium

News Thumbnail
8:00 AM | Monday | Sep 28, 2026 PRNewsWire

U.S. FDA Approves AbbVie's JUVMO™ (tavapadon) for Parkinson's Disease

News Thumbnail
8:00 AM | Tuesday | Sep 22, 2026 PRNewsWire

Allergan Aesthetics Debuts AA Signature™ in the United States with SKIN360, Its First Multimodal Consultation Approach

News Thumbnail
2:00 AM | Tuesday | Sep 22, 2026 PRNewsWire

AbbVie Announces European Commission Approval of RINVOQ® (upadacitinib) for the Treatment of Children with Active Polyarticular Juvenile Idiopathic Arthritis

News Thumbnail
8:00 AM | Monday | Sep 21, 2026 PRNewsWire

AbbVie and Iambic Announce Collaboration to Accelerate AI-driven Drug Discovery

News Thumbnail
8:30 AM | Friday | Sep 18, 2026 PRNewsWire

AbbVie Highlights New Real-World Data Supporting the Effectiveness of VRAYLAR® (cariprazine) at Psych Congress 2026

News Thumbnail
8:30 AM | Thursday | Sep 17, 2026 PRNewsWire

AbbVie to Present Phase 3 Etentamig Results and Data from Broad Multiple Myeloma Portfolio at the 2026 International Myeloma Society (IMS) Meeting

News Thumbnail
8:00 AM | Thursday | Sep 17, 2026 PRNewsWire

Allergan Aesthetics Presents New Clinical Data Evaluating Skin Quality Improvements in Individuals Taking Medical Weight Loss Medications

News Thumbnail
8:00 AM | Tuesday | Sep 15, 2026 PRNewsWire

Allergan Aesthetics to Advance Scientific Dialogue on Skin Longevity, Aging Biology and Exosome Science at the 2026 Science of Skin Summit

News Thumbnail

AbbVie Partners with Valkai to Apply Advanced AI Across Targeted Areas of Clinical Development

PRNewsWire

9:00 AM | Tuesday | Sep 29, 2026

news photo
Loading...

AbbVie deepens investment in artificial intelligence (AI) by entering into a new collaboration with Valkai to strengthen integrated AI capabilities across clinical development AbbVie is committed to integrating AI throughout the drug development journey to advance scientific innovation, strengthen operations and improve outcomes for patients NORTH CHICAGO, Ill., Sept. 29, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV) is investing in its artificial intelligence (AI) infrastructure through a new partnership with Valkai, a life sciences AI platform designed to help accelerate the pace at which scientific innovation reaches patients.

Read full article redirect
9:00 AM | Tuesday | Sep 29, 2026

AbbVie Partners with Valkai to Apply Advanced AI Across Targeted Areas of Clinical Development

PRNewsWire

AbbVie deepens investment in artificial intelligence (AI) by entering into a new collaboration with Valkai to strengthen integrated AI capabilities across clinical development AbbVie is committed to integrating AI throughout the drug development journey to advance scientific innovation, strengthen operations and improve outcomes for patients NORTH CHICAGO, Ill., Sept. 29, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV) is investing in its artificial intelligence (AI) infrastructure through a new partnership with Valkai, a life sciences AI platform designed to help accelerate the pace at which scientific innovation reaches patients.

Read full article arrow
News Thumbnail
8:00 AM | Tuesday | Sep 29, 2026

Ginkgo Datapoints and Apheris Welcome AbbVie, argenx, Lundbeck, and Takeda as Founding Members of the Antibody Developability Consortium

Business Wire

BOSTON--(BUSINESS WIRE)--Ginkgo Datapoints and Apheris welcome AbbVie, argenx, Lundbeck, and Takeda as Founding Members of the Antibody Developability Consortium.

Read full article arrow
News Thumbnail
8:00 AM | Monday | Sep 28, 2026

U.S. FDA Approves AbbVie's JUVMO™ (tavapadon) for Parkinson's Disease

PRNewsWire

JUVMO™ is the first and only selective D1/D5 receptor agonist approved for adults with Parkinson's disease1 Taken once daily with or without levodopa therapy, JUVMO offers patients a differentiated approach to motor symptom control across the Parkinson's disease continuum Approval is supported by the Phase 3 TEMPO program demonstrating significant improvements in daily functioning, increased "on" time without troublesome dyskinesia and a favorable safety profile NORTH CHICAGO, Ill., Sept. 28, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that the U.S. Food and Drug Administration (FDA) has approved JUVMO™ (tavapadon) tablets as the first and only selective D1/D5 receptor agonist for the treatment of adults with Parkinson's disease, a progressive neurological disorder that affects millions of people worldwide.

Read full article arrow
News Thumbnail
8:00 AM | Tuesday | Sep 22, 2026

Allergan Aesthetics Debuts AA Signature™ in the United States with SKIN360, Its First Multimodal Consultation Approach

PRNewsWire

AA Signature: SKIN360 marks the first in a series of assessment protocols addressing patients' evolving aesthetic goals. The program includes provider education and resources to support 96% of patients who are interested in a comprehensive aesthetic consultation.

Read full article arrow
News Thumbnail
2:00 AM | Tuesday | Sep 22, 2026

AbbVie Announces European Commission Approval of RINVOQ® (upadacitinib) for the Treatment of Children with Active Polyarticular Juvenile Idiopathic Arthritis

PRNewsWire

RINVOQ is now approved in the European Union for the treatment of active polyarticular juvenile idiopathic arthritis (pJIA) in patients two years of age and older who have responded inadequately to, or who are intolerant to, one or more DMARDs 1 Approval was based on the open-label Phase 1 SELECT-YOUTH study and data from adults with rheumatoid arthritis 1,2 A new oral solution of RINVOQ was approved for use in patients with pJIA 1 RINVOQ is currently approved in the European Union for 11 indications across various immune-mediated, inflammatory diseases 1 NORTH CHICAGO, Ill., Sept. 22, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that the European Commission (EC) has approved RINVOQ® (upadacitinib; 15 mg tablet and weight-based 1 mg/mL oral solution) for the treatment of active polyarticular juvenile idiopathic arthritis (polyarticular rheumatoid factor... Read more

Read full article arrow
News Thumbnail
8:00 AM | Monday | Sep 21, 2026

AbbVie and Iambic Announce Collaboration to Accelerate AI-driven Drug Discovery

PRNewsWire

Multi-year partnership applies Iambic's AI platform to speed up small molecule drug discovery in immunology, neuroscience and oncology Companies to pursue programs with both first-in-class and best-in-class potential, combining Iambic's molecular superintelligence platform with AbbVie's therapeutic area expertise NORTH CHICAGO, Ill. and SAN DIEGO, Sept.

Read full article arrow
News Thumbnail
8:30 AM | Friday | Sep 18, 2026

AbbVie Highlights New Real-World Data Supporting the Effectiveness of VRAYLAR® (cariprazine) at Psych Congress 2026

PRNewsWire

New data from prospective real-world studies of VRAYLAR showed meaningful improvements in depressive symptoms, functioning and quality of life among adults living with major depressive disorder (MDD) and bipolar I (BP-I) depression These findings provide additional evidence that the benefits observed with VRAYLAR in clinical trials can also be achieved in routine practice, where patients often have more complex treatment needs NORTH CHICAGO, Ill., Sept. 18, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV) today presented new VRAYLAR® (cariprazine) data at Psych Congress 2026 in New Orleans, including results from two prospective real-world observational studies in major depressive disorder (MDD) and bipolar I disorder (BP-I).

Read full article arrow
News Thumbnail
8:30 AM | Thursday | Sep 17, 2026

AbbVie to Present Phase 3 Etentamig Results and Data from Broad Multiple Myeloma Portfolio at the 2026 International Myeloma Society (IMS) Meeting

PRNewsWire

Plenary presentation will feature Phase 3 CERVINO results demonstrating that etentamig met the study's dual primary endpoints of objective response rate (ORR) and progression-free survival (PFS) in relapsed/refractory multiple myeloma (RRMM) Additional presentations highlight research across the breadth of AbbVie's multiple myeloma portfolio, including ABBV-2001 (ISB 2001), a trispecific T-cell engager and surzetoclax, a BCL-2 inhibitor, and combination approaches AbbVie's IMS presence reinforces its strategy to build a differentiated multiple myeloma portfolio across complementary mechanisms designed to address disease complexity and evolving patient needs NORTH CHICAGO, Ill., Sept. 17, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV) announced today that new data from its broad multiple myeloma research portfolio will be featured at the 23rd International Myeloma Society (IMS) Annual Meeting, taking place September 23-26, 2026, in Glasgow, Scotland.

Read full article arrow
News Thumbnail
8:00 AM | Thursday | Sep 17, 2026

Allergan Aesthetics Presents New Clinical Data Evaluating Skin Quality Improvements in Individuals Taking Medical Weight Loss Medications

PRNewsWire

Two studies evaluating targeted skincare and dermabrasion approaches will be presented at the 2026 Science of Skin Summit IRVINE, Calif., Sept. 17, 2026 /PRNewswire/ -- Allergan Aesthetics, an AbbVie company (NYSE: ABBV), today announced results from two single-center clinical studies evaluating targeted skincare regimens alone and in combination with DiamondGlow® dermabrasion treatments in individuals taking medical weight loss (MWL) medications, including glucagon-like peptide-1 receptor agonists (GLP-1 RAs).

Read full article arrow
News Thumbnail
8:00 AM | Tuesday | Sep 15, 2026

Allergan Aesthetics to Advance Scientific Dialogue on Skin Longevity, Aging Biology and Exosome Science at the 2026 Science of Skin Summit

PRNewsWire

R&D leaders to lead discussions on the hallmarks of aging, emerging exosome research and evidence-based innovation shaping regenerative aesthetics. A featured SkinMedica ® R&D panel on exosomes will introduce the FACTS Principles and examine the scientific questions shaping responsible innovation in this rapidly evolving category.

Read full article arrow
News Thumbnail